ЭПИДЕМИОЛОГИЧЕСКИЕ ОСОБЕННОСТИ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ В СЕВЕРО-ЗАПАДНОМ РЕГИОНЕ РОССИИ (РЕЗУЛЬТАТЫ ОТКРЫТОГО МНОГОЦЕНТРОВОГО ПРОСПЕКТИВНОГО ИССЛЕДОВАНИЯ DIREG 2)

Людмила Константиновна Пальгова; Андрей Юрьевич Барановский; Татьяна Игоревна Ушакова; Алина Сергеевна Юркина; Дмитрий Владиславович Блинов

doi:10.21638/11701/spbu11.2017.201

Authors

Людмила Константиновна Пальгова St Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation
Андрей Юрьевич Барановский St Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation
Татьяна Игоревна Ушакова St Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation
Алина Сергеевна Юркина St Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation
Дмитрий Владиславович Блинов St Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation

DOI:

https://doi.org/10.21638/11701/spbu11.2017.201

Abstract

Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as an important problem that can lead to cirrhosis and hepatic failure. It may be the most prevalent liver disease. However,knowledge of the epidemiology is limited. These findings encourage to conduct a larger sample size study to evaluate the real prevalence of NAFLD in the Russian population. It is important to know current prevalence of NAFLD. DIREG 2 study was performed under umbrella of leading Russian professional societies in partnership with Sanofi Russia. Objective: to estimate the prevalence of NAFLD within the general practitioner’s and gastroenterologist’s patient flow. It is important to know current prevalence of NAFLD in North-West region and to compare with DIREG 2 results. Materials and methods.
Epidemiologic, observational, multicenter study assessing the prevalence of NAFLD among patients outpatient practice. A total of 50 145 patients (3769 in North-West region) including those suspected of having NAFLD criteria were enrolled in the Program. The investigators were qualified doctors (GPs \ therapist’s \ gastroenterologists), providing outpatient care for the population. The epidemiological data were obtained, recorded during two routine patient visits to investigating centers. Study results. Percentage of patients with revealed NAFLD within the patient flow primary or consistently coming to selected doctors for any reason including those suspected of having NAFLD was 37,3 % in Russia vs 49,1 % in North West Region. Conclusion. Prevalence of NAFLD among patient flow of doctors in Russia is quite high. It has been revealed a high prevalence of NANCFLD within the patient flow primary or consistently coming to selected by doctors for any reason. Refs 55. Figs 4. Table 1.

Keywords:

DIREG 2, epidemiology, NAFLD, non-alcoholic fatty liver disease, NASH, nonalcoholic steatohepatitis, prevalence

Downloads

Download data is not yet available.

References

Литература

Aithal G. P., Das K., Chowdhury A. Epidemiology of nonalcoholic fatty liver disease (NAFLD) // GI Epidemiology: Diseases and Clinical Methodology. 2nd ed. Wiley-Blackwell, 2014. Р. 357–372.

Gonciarz Z., Besser P., Lelek E., Gundermann K. J., Johannes K. J. Randomized placebo-controlled double-blind trial on «essential» phospholipids in the treatment of fatty liver associated with diabetes // Med. Chir. Digest. 1988. Vol. 17. P. 61–85.

Ludwig J., Viggiano T. R., McGill D. B., Oh B. J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease // Mayo Clin. Proc. 1980. Vol. 55. P. 434–438.

Макаров И. О., Боровкова Е. И., Казаков Р. Д. Распространенность неалкогольной жировой болезни печени у беременных с ожирением // Акушерство, гинекология и репродукция. 2012. № 4. C. 18–21.

Hamaguchi M., Kojima T., Takeda N., Nagata C., Takeda J., Sarui H., Kawahito Y., Yoshida N., Suetsugu A., Kato T., Okuda J., Ida K., Yoshikawa T. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease // World J. Gastroenterol. 2007. Vol. 13. P. 1579–1584.

Haring R., Wallaschofski H., Nauck M., Dörr M., Baumeister S. E., Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl-transpeptidase // Hepatology. 2009. Vol. 50. P. 1403–1411.

Lazo M., Hernaez R., Bonekamp S., Kamel I. R., Brancati F. L., Guallar E., Clark J. M. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study // BMJ. 2011. Vol. 343. d6891.

Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? // Diabetologia. 2008. Vol. 51. P. 1947–1953.

Sookoian S., Pirola C. J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review // Journal of hepatology. 2008. Vol. 49, N 4. P. 600–607.

Goland S., Shimoni S., Zornitzki T., Knobler H., Azoulai O., Lutaty G., Melzer E., Orr A., Caspi A., Malnick S. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment // Journal of clinical gastroenterology. 2006. Vol. 40, N 10. P. 949–955.

Бокерия Л. А., Ступаков И. Н., Самородская И. В., Ботнарь Ю. М. Сердечно-сосудистые заболевания в Российской Федерации на рубеже веков: смертность, распространенность, факторы риска // Бюллетень НЦССХ им. А. Н. Бакулева РАМН. 2007. Т. 8, № 5. C. 5–11.

Корнеева О. Н., Драпкина О. М. Неалкогольная жировая болезнь печени у пациентов с метаболическим синдромом // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2007. Т. 1, № 17. С. 65.

McCullough A. J. Epidemiology of the metabolic syndrome in the USA // Journal of digestive diseases. 2011. Vol. 12, N 5. P. 333–340.

Мамедов М. Н., Оганов Р. Г. Метаболический синдром в реальных клинико-амбулаторных условиях: принципы диагностики и лечения // Профилактика заболеваний и укрепление здоровья. 2005. Т. 8, № 6. С. 41–45.

Драпкина О. М., Корнеева О. Н., Ивашкин В. Т. Терапия неалкогольного стеатогепатита при метаболическом синдроме: фокус на эссенциальные фосфолипиды // Лечащий врач. 2010. Т. 2. С. 43–45.

Schwimmer J. B., Deutsch R., Kahen T., Lavine J. E., Stanley C., Behling C. Prevalence of fatty liver in children and adolescents // Pediatrics. 2006. Vol. 118, N 4. P. 1388–1393.

Поливанов В. А. Фармакоэкономический анализ терапии алкогольной болезни печени в стадии стеатоза и гепатита препаратами Эссливер Форте и Эссенциале Форте Н // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2009. № 1. С. 7–11.

Драпкина О. М., Ивашкин В. Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014. № 4. С. 32–38.

Drapkina O., Evsyutina Y., Ivashkin V. Prevalence of non-alcoholic fatty liver disease in the Russian Federation: the open, multicenter, prospective study, DIREG 1 // American Journal of Clinical Medicine Research. 2015. Vol. 3 (2). P. 31–36.

Drapkina O. M., Ivashkin V. T. Liver disease structure explored in Russian Federation: national-wide DIREG-L-01903 study for non-alcoholic fatty liver disease screening // Journal of Hepatology. 2011. Vol. 54. P. 332.

Цуканов В. В., Тонких Ю. Л., Каспаров Э. В., Куперштейн Е. Ю., Амельчугова О. С., Лукичева Э. В., Васютин А. В. Hеалкогольная жировая болезнь печени у взрослого городского населения России (Распространенность и факторы риска) // Врач. 2010. № 9. С. 1–4.

Ивашкин В. Т., Драпкина О. М., Маев И. В., Трухманов А. С., Блинов Д. В., Пальгова Л. К., Цуканов В. В., Ушакова Т. И. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования

DIREG 2 // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015. № 6.С. 31–41.

Ivashkin V. T., Drapkina O. M., Maev I. V., Troukhmanov A. S., Zimovina U. V., PalgovaL. K., Blinov D. V., Shirokova E. N., Tsukanov V. V. Non-alcoholic fatty liver disease risk factors assessment among the general practitioners and gastroenterologist’s patients flow // United European Gastroenterology Journal. 2015. Vol. 3 (1). P. 344–345.

Alberti K. G., ZimmetP., ShawJ. Themetabolicsyndrome — anewworldwidedefinition // Lancet. 2005. Vol. 366 (9491). P. 1059–1062.

Grundy S. M., Cleeman J. I., Daniels S. R., Donato K. A., Eckel R. H., Franklin B. A., Gordon D. J., Krauss R. M., Savage P. J., Smith S. C. Jr., Spertus J. A., Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association / National Heart, Lung, and Blood Institute Scientific Statement // Circulation. 2005. Vol. 112 (17). P. 2735–2752.

Browning J. S., Szczepaniak L. S., Dobbings L. S., Nuremberg P., Horton J. D., Cohen J. C., Grundy S. M., Hobbs H. H. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity // Hepatology. 2004. Vol. 40 (7). P. 1387–1395.

Neuschwander-Tetri B. A., Caldwell S. H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference // Hepatology. 2003. Vol. 37. P. 1202–1219.

Nomura H., Kashiwaqi S., Hayashi J., Kajiyama W., Tani S., Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan // Jap. J. Med. 1998. Vol. 27 (1). P. 142–149.

De Alwis N. M., Day C. P. Non-alcoholic fatty liver disease: the mist gradually clears // J. Hepatol. 2008. Vol. 48 (suppl. 1). P. 104–112.

Sanyal A. J., Banas C., Sargeant C., Luketic V. A., Sterling R. K., Stravitz R. T., Shiffman M. L., Heuman D., Coterrell A., Fisher R. A., Contos M. J., Mills A. S. Similarities and differences in outcomes of cirrhosis due to non-alcoholic steatohepatitis and hepatitis C // Hepatology. 2006. Vol. 43. P. 682–689.

Игнатьева В. И., Авксентьева М. В. Анализ методологических особенностей исследований по изучению социально-экономического бремени заболеваний в РФ в рамках разработки стандартной методики анализа стоимости болезни с целью ее использования в оценке технологий здравоохранения // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2014.№ 3. С. 3–11.

Макаров И. О., Павлов Ч. С., Шеманаева Т. В., Воеводин С. М., Муравей А. Ю. Современный взгляд на проблему лечения хронического гепатита во время беременности // Акушерство, гинекология и репродукция. 2013. № 1. С. 22–25.

Шульпекова Ю. О. Неалкогольная жировая болезнь печени: патогенез, диагностика, лечение // Фарматека. 2007. Т. 141, № 6. С. 48–53.

Arvind N., Savaikar P., Rajkumar J. Therapy for NAFLD. A comparative study of essential phospholypids vs ursodeoxycholic acid // Indian J. Clin. Pract. 2006. Vol. 16. P. 21–24.

Лазебник Л. Б., Звенигородская Л. А. Метаболический синдром и органы пищеварения. М., 2009. 182 с.

De Denus S., Spinier S. A., Miller K. Statins and liver toxicity: ameta-analysis // Pharmactiherapy. 2004. Vol. 24, N 5. P. 584–591.

Lazo M., Solga S. F., Horska A., Bonekamp S., Diehl A. M., Brancati F. L. Wagenknecht L. E, Pi-Sunyer F. X., Kahn S. E., Clark J. M. Effect of a 12-month intensive life style intervention on hepaticsteato-sisinadults with type 2 diabetes // Diabetes Care. 2010. Vol. 3. P. 2156–2163.

Ивашкин В. Т., Маевская М. В., Павлов Ч. С., Широкова Е. Н., Буеверов А. О., Драпкина О. М., Шульпекова Ю. О., Цуканов В. В., Маммаев С. Н., Маев И. В., Пальгова Л. К., Тихонов И. Н. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016. № 2. С. 24–42. URL: http://www.gastro-j.ru/files/24_42_1461884541.pdf (дата обращения 17.08.2016).

Липатова Л. В. Нейроиммунные механизмы эпилепсии как ключ к патогенетическому лечению заболевания // Эпилепсия и пароксизмальные состояния. 2010. № 3. С. 20–27.

Ivashkin V. T., Drapkina O. M., Maev I. V., Troukhmanov A. S., Zimovina U. V., Palgova L. K., Blinov D. V., Shirokova E. N., Tsukanov V. V. Non-alcoholic fatty liver disease risk factors assessment among the general practitioners and gastroenterologist’s patients flow // United European Gastroenterology Journal. 2015. Vol. 3 (1). P. 344–345.

Gundermann K. J., Kuenker A., Kuntz E., Droździk M. Activity of essential phospholipids (EPL) from soybean in liver diseases // Pharmacol. Rep. 2011. Vol. 63. P. 643–659.

Strecker A. Ubereinigeneue Bestandtheileder Schweingalle // Ann. Chem. Pharmacie. 1862. Vol. 123. P. 353–360.

Argo С. K., Loria P., Caldwell S. H., Lonardo A. Statinsinliverdisease: amolehill, an iceberg, or neither? // Hepatology. 2008. Vol. 48, N 2. P. 662–669.

Василенко И. А., Долгова Г. В., Сорокоумова Г. М., Хайретдинов М. Н., Померанцева Т. Я. Сравнительное изучение гепатопротекторных препаратов Эссенциале Форте Н, Фосфоглив, Эссливер Форте // РМЖ. Гастроэнтерология. 2013. № 13.

Гуревич К. Г. Какие фосфолипиды «эссенциальнее»? // Клиническая фармакокинетика. 2004. № 1. С. 52–57.

Du Q. Treatment of 52 cases with hepatic dysfunctional fatty liver with Essentiale® // Chin. J. Gastroenterol.Hepatol. 2004. Vol. 13. P. 21–24.

Liang H. Discussion of treatment of fatty liver using polyene phosphatidylcholine capsules // Chinese Med. Fact. Mine. 2006. Vol. 19. P. 43.

Cairella M., Callisto F., Godi R., Marchini G. Polyunsaturated phosphatidylcholine combined with vitamin B complex in the treatment of patients with disorders of the hepatobiliary function caused by unbalanced nutrition // Clin. Ter. 1989. Vol. 131 (4). P. 237–246.

Sun C., Zheng X., Tan Z., Cui F., Zhang R., Zhang H. Clinical observation on polyene phosphatidylcholine and metformin in the treatment of type-2 diabetes and non-alcoholic fatty liver disease // Clin. Focus. 2008. Vol. 23, N 17.

Yin D., Kong L. Observation for curative effect of Essentiale® in treatment of fatty liver caused by diabetes mellitus // Med. J. Qilu. 2000. Vol. 15. P. 277–278.

Pacifico L., Chiesa C., Anania C., De Merulis A., Osborn J. F. Romaggioli S., Gaudio E. Nonalcoholic fatty liver diseaseand the heart in children and adolescents // World J. Gastroenterol. 2014. Vol. 20. P. 9055–9071.

Forse R. A., Krishnamurty D. M. Epidemiology and discrimination inobesity // The ASMBS textbook of bariatric surgery. New York: Springer, 2015. Vol. 1. P. 3–12.

Рзаева Р. Н., Мозговая Е. В., Пальгова Л. К. Стеатоз печени у женщин с ожирением. Особенности течения беременности // Журнал акушерства и женских болезней. 2014. Т. LXIII, вып. 6. С. 55–65.

Рзаева З. Н., Мозговая Е. В., Пальгова Л. К., Прокопенко В. М., Тумасова Ж. Н. Особенности течения беременности у женщин при стетозе печени и ожирении // Журнал акушерства и женских болезней. 2013. Т. LXII, вып. 6. С. 47–54.

EASL — EASD — EASO Clinical Practice Guidelines for the management of non-alcoholic fatty

liver disease. URL: http://www.journal-of-hepatology.eu/article/S0168-8278(15)00734-5/pdf (дата обращения 23.09.2016).

References

Aithal G. P., Das K., Chowdhury A. Epidemiology of nonalcoholic fatty liver disease (NAFLD). GI epidemiology: Diseases and clinical methodology. 2nd ed. Wiley-Blackwell, 2014, pp. 357–372.

Gonciarz Z., Besser P., Lelek E., Gundermann K. J., Johannes K. J. Randomized placebo-controlled

double-blind trial on «essential» phospholipids in the treatment of fatty liver associated with diabetes. Med.

Chir. Digest., 1988, vol. 17, pp. 61–85.

Ludwig J., Viggiano T. R., McGill D. B., Oh B. J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc., 1980, vol. 55, pp. 434–438.

Makarov I. O., Borovkova E. I., Kazakov R. D. Rasprostranennost’ nealkogol’noi zhirovoi bolezni pecheni u beremennykh s ozhireniem [Prevalence of non-alcoholic fatty liver disease among obese pregnant women]. Akusherstvo, ginekologiia i reproduktsiia [Obstetrics, Gynecology and Reproduction], 2012, no. 4, pp. 18–21. (In Russian)

Hamaguchi M., Kojima T., Takeda N., Nagata C., Takeda J., Sarui H., Kawahito Y., Yoshida N., Suetsugu A., Kato T., Okuda J., Ida K., Yoshikawa T. Nonalcoholic fatty liver disease is a novel predictor of

cardiovascular disease . World J. Gastroenterol, 2007, vol. 13, pp. 1579–1584.

Haring R., Wallaschofski H., Nauck M., Dörr M., Baumeister S. E., Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl-transpeptidase

levels. Hepatology, 2009, vol. 50, pp. 1403–1411.

Lazo M., Hernaez R., Bonekamp S., Kamel I. R., Brancati F. L., Guallar E., Clark J. M. Non-alcoholic

fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011, vol. 343.

d6891.

Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia, 2008, vol. 51, pp. 1947–1953.

Sookoian S., Pirola C. J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review // Journal of hepatology, 2008, vol. 49, no. 4, pp. 600–607.

Goland S., Shimoni S., Zornitzki T., Knobler H., Azoulai O., Lutaty G., Melzer E., Orr A., Caspi A.,

Malnick S. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic

and tissue Doppler imaging assessment. Journal of clinical gastroenterology, 2006, vol. 40, no. 10,

pp. 949–955.

Bokeriia L. A., Stupakov I. N. Samorodskaia I. V. Botnar’ Iu. M. Serdechno-sosudistye zabolevaniia v Rossiiskoi Federatsii na rubezhe vekov: smertnost’, rasprostranennost’, faktory riska [Cardiovascular diseases in the Russian Federation at the turn of the century: mortality, prevalence, risk factors]. Biulleten’ NTsSSKh im. A. N. Bakuleva RAMN [Bulletin NTsSSh them. A. N. Bakulev RAMS], 2007, vol. 8, no. 5, pp. 5–11. (In Russian)

Korneeva O. N., Drapkina O. M. Nealkogol’naia zhirovaia bolezn’ pecheni u patsientov s metabolicheskim sindromom [Non-alcoholic fatty liver disease in women with metabolic syndrome]. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii [Russian J. gastroenterology, hepatology and coloproctology], 2007, vol. 1, no. 17, pp. 65. (In Russian)

McCullough A. J. Epidemiology of the metabolic syndrome in the USA. Journal of digestive diseases,2011, vol. 12, no. 5, pp. 333–340.

Mamedov M. N., Oganov R. G. Metabolicheskii sindrom v real’nykh kliniko-ambulatornykh usloviiakh: printsipy diagnostiki i lecheniia [Metabolic syndrome in real clinical and outpatient settings: principles

of diagnosis and treatment]. Profilaktika zabolevanii i ukreplenie zdorov’ia [Disease prevention and health promotion], 2005, vol. 8, no. 6, pp. 41–45. (In Russian)

Drapkina O. M., Korneeva O. N., Ivashkin V. T. Terapiia nealkogol’nogo steatogepatita pri metabolicheskom sindrome: fokus na essentsial’nye fosfolipidy [Treatment of nonalcoholic steatohepatitis and metabolic syndrome: focus on essential phospholipids]. Lechashchii vrach [Therapist], 2010, no. 2, pp. 43–45. (In Russian)

Schwimmer J. B., Deutsch R., Kahen T., Lavine J. E., Stanley C., Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics, 2006, vol. 118, no. 4, pp. 1388–1393.

Polivanov V. A. Farmakoekonomicheskii analiz terapii alkogol’noi bolezni pecheni v stadii steatoza i gepatita preparatami Essliver Forte i Essentsiale Forte N [Pharmacoeconomic analysis of treatment of

alcoholic liver disease in the stage of steatosis and hepatitis drugs and Essliver Forte Essentiale Forte N]. Farmakoekonomika. Sovremennaia farmakoekonomika i farmakoepidemiologiia [Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology], 2009, no. 1, pp. 7–11. (In Russian)

Drapkina O. M., Ivashkin V. T. Epidemiologicheskie osobennosti nealkogol’noi zhirovoi bolezni

pecheni v Rossii [Epidemiological features of nonalcoholic fatty liver disease in Russia]. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii [Russian J. gastroenterology, hepatology and coloproctology] , 2014, no. 4, pp. 32–38. (In Russian)

Drapkina O., Evsyutina Y., Ivashkin V. Prevalence of non-alcoholic fatty liver disease in the Russian Federation: the open, multicenter, prospective study, DIREG 1. American Journal of Clinical Medicine Research, 2015, vol. 3(2), pp. 31–36.

Drapkina O. M., Ivashkin V. T. Liver disease structure explored in Russian Federation: national-wide DIREG-L-01903 study for non-alcoholic fatty liver disease screening. Journal of Hepatology, 2011, vol. 54, p. 332.

Tsukanov V. V., Tonkikh Iu. L., Kasparov E. V. Kupershtein E. Yu., Amel’chugova O. S., Lukicheva

E. V., Vasiutin A. V. Nealkogol’naia zhirovaia bolezn’ pecheni u vzroslogo gorodskogo naseleniia Rossii

(Rasprostranennost’ i faktory riska) [Nonalcoholic fatty liver disease in the adult urban population of Russia

(Prevalence and risk factors)]. Vrach [Doctor], 2010, no. 9, pp. 1–4. (In Russian)

Ivashkin V. T., Drapkina O. M., Maev I. V., Trukhmanov A. S., Blinov D. V., Pal’gova L. K., Tsukanov

V. V., Ushakova T. I. Rasprostranennost’ nealkogol’noi zhirovoi bolezni pecheni u patsientov ambulatorno-

poliklinicheskoi praktiki v Rossiiskoi Federatsii: rezul’taty issledovaniia DIREG 2 [Non-alcoholic fatty liver disease prevalence among patient’s outpatient practice of the Russian Federation: DIREG 2 study results]. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii [Russian J. gastroenterology, hepatology and coloproctology], 2015, no. 6, pp. 31–41. (In Russian)

Ivashkin V. T., Drapkina O. M., Maev I. V., Troukhmanov A. S., Zimovina U. V., Palgova L. K.,Blinov D. V., Shirokova E. N., Tsukanov V. V. Non-alcoholic fatty liver disease risk factors assessment among the general practitioners and gastroenterologist’s patients flow. United European Gastroenterology Journal, 2015, vol. 3 (1), pp. 344–345.

Alberti K. G., Zimmet P., Shaw J. The metabolic syndrome — a new worldwide definition. Lancet,2005, vol. 366 (9491), pp. 1059–1062.

Grundy S. M., Cleeman J. I., Daniels S. R., Donato K. A., Eckel R. H., Franklin B. A., Gordon D. J., Krauss R. M., Savage P. J., Smith S. C. Jr., Spertus J. A., Costa F. Diagnosis and management of the metabolic

syndrome: an American Heart Association / National Heart, Lung, and Blood Institute Scientific Statement.

Circulation, 2005, vol. 112 (17), pp. 2735–2752.

Browning J. S., Szczepaniak L. S., Dobbings L. S., Nuremberg P., Horton J. D., Cohen J. C., Grundy

S. M., Hobbs H. H. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology, 2004, vol. 40 (7), pp. 1387–1395.

Neuschwander-Tetri B. A., Caldwell S. H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology, 2003, vol. 37, pp. 1202–1219.

Nomura H., Kashiwaqi S., Hayashi J., Kajiyama W., Tani S., Goto M. Prevalence of fatty liver in a

general population of Okinawa, Japan. Jap. J. Med., 1998, vol. 27 (1), pp. 142–149.

De Alwis N. M., Day C. P. Non-alcoholic fatty liver disease: the mist gradually clears. J. Hepatoogy, 2008, vol. 48 (suppl. 1), pp. 104–112.

Sanyal A. J., Banas C., Sargeant C., Luketic V. A., Sterling R. K., Stravitz R. T., Shiffman M. L., Heuman D., .Coterrell A., Fisher R. A., Contos M. J., Mills A. S. Similarities and differences in outcomes of cirrhosis

due to non-alcoholic steatohepatitis and hepatitis C. Hepatology, 2006, vol. 43, pp. 682–689.

Ignat’eva V. I., Avksent’eva M. V. Analiz metodologicheskikh osobennostei issledovanii po izucheniiu sotsial’no-ekonomicheskogo bremeni zabolevanii v RF v ramkakh razrabotki standartnoi metodiki analiza stoimosti bolezni s tsel’iu ee ispol’zovaniia v otsenke tekhnologii zdravookhraneniia [The analysis of methodologic characteristics of researches on social and economic burden of diseases in Russia in the frames of

development of standard cost of illness methodology for the health technology assessment]. Farmakoekonomika. Sovremennaia farmakoekonomika i farmakoepidemiologiia [Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology], 2014, no. 3, pp. 3–11. (In Russian)

Makarov I. O., Pavlov Ch. S., Shemanaeva T. V., Voevodin S. M., Muravei A. Iu. Sovremennyi vzgliad na problemu lecheniia khronicheskogo gepatita vo vremia beremennosti [The modern view on the problem of treatment of chronic hepatitis B during pregnancy]. Akusherstvo, ginekologiia i reproduktsiia [Obstetrics, Gynecology and Reproduction], 2013, no. 1, pp. 22–25. (In Russian)

Shulpekova Yu. O. Nealkogol’naia zhirovaia bolezn’ pecheni: patogenez, diagnostika, lechenie [Nonalcoholic fatty liver disease: pathogenesis, diagnosis, treatment]. Farmateka [Pharmateka], 2007, vol. 141, no. 6, pp. 48–53. (In Russian)

Arvind N., Savaikar P., Rajkumar J. Therapy for NAFLD. A comparative study of essential phospholypids vs ursodeoxycholic acid. Indian. J. Clin. Pract., 2006, vol. 16, pp. 21–24.

Lazebnik L. B., Zvenigorodskaia L. A. Metabolicheskii sindrom i organy pishchevareniia [Metabolic syndrome and digestive organs]. Мoscow, 2009 182 p. (In Russian)

De Denus S., Spinier S. A., Miller K. Statins and livertoxicity: a meta-analysis. Pharmactiherapy, 2004, vol. 24, no. 5, pp. 584–591.

Lazo M., Solga S. F., Horska A., Bonekamp S., Diehl A. M., Brancati F. L. Wagenknecht L. E, Pi-Sunyer F. X., Kahn S. E., Clark J. M. Effect of a 12-month intensive life style intervention on hepaticsteato-sisinadults with type 2 diabetes. Diabetes Care, 2010, vol. 3, pp. 2156–2163.

Ivashkin V. T., Maevskaia M. V., Pavlov Ch. S., Shirokova E. N., Bueverov A. O., Drapkina O. M.,

Shul’pekova Iu. O., Tsukanov V. V., Mammaev S. N., Maev I. V., Pal’gova L. K., Tikhonov I. N. Klinicheskie

rekomendatsii po diagnostike i lecheniiu nealkogol’noi zhirovoi bolezni pecheni Rossiiskogo obshchestva

po izucheniiu pecheni i Rossiiskoi gastroenterologicheskoi assotsiatsii [Clinical guidelines for the diagnosis

and treatment of non-alcoholic fatty liver disease, the Russian Society for the Liver Study and the Russian

Gastroenterological Association]. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii [Russian

J. gastroenterology, hepatology and coloproctology], 2016, no. 2, pp. 24–42. Available at: http://www.gastro-j.ru/files/24_42_1461884541.pdf (accessed: 17.08.2016). (In Russian)

Lipatova L. V. Neiroimmunnye mekhanizmy epilepsii kak kliuch k patogeneticheskomu lecheniiu

zabolevaniia [Neuro-immune mechanism of epilepsy as a key to pathogenetic treatment of the disease]. Epilepsiia i paroksizmal’nye sostoianiia [Epilepsy and Paroxismal Conditions],2010, no. 2 (3), pp. 20-27. (In Russian)

Ivashkin V. T., Drapkina O. M., Maev I. V., Troukhmanov A. S., Zimovina U. V., Palgova L. K.,

Blinov D. V., Shirokova E. N., Tsukanov V. V. Non-alcoholic fatty liver disease risk factor sassessment among

the general practitioners and gastroenterologist’s patients flow. United European Gastroenterology Journal,2015, vol. 3 (1), pp. 344–345.

Gundermann K. J., Kuenker A., Kuntz E., Droździk M. Activity of essential phospholipids (EPL)

from soybean in liver diseases. Pharmacol. Rep., 2011, vol. 63, pp. 643–659.

Strecker A. Ubereinigeneue Bestandtheileder Schweingalle. Ann. Chem. Pharmacie, 1862, vol. 123,pp. 353–360.

Argo С. K., Loria P., Caldwell S. H., Lonardo A. Statins in liver disease: a molehill, an iceberg, or

neither? Hepatology, 2008, vol. 48, no. 2, pp. 662–669.

Vasilenko I. A., Dolgova G. V., Sorokoumova G. M., Khairetdinov M. N., Pomerantseva T. Ia.

Sravnitel’noe izuchenie gepatoprotektornykh preparatov Essentsiale Forte N, Fosfogliv, Essliver Forte

[Comparative study of hepatoprotective drugs Essentiale Forte N, Phosphogliv, Essliver Forte]. RMZh. Gastroenterologiia [RMJ. Gastroenterology], 2013, no. 13. (In Russian)

Gurevich K. G. Kakie fosfolipidy «essentsial’nee»? [What phospholipids are more «essential»?] . Klinicheskaia farmakokinetika [Clinical pharmacokinetics], 2004, no. 1, pp. 52–57.

(In Russian)

Du Q. Treatment of 52 cases with hepatic dysfunctional fatty liver with Essentiale®. Chin. J. Gastroenterol. Hepatol., 2004, vol. 13, pp. 21–24.

Liang H. Discussion of treatment of fatty liver using polyene phosphatidylcholine capsules . Chinese Med. Fact. Mine, 2006, vol. 19.

Cairella M., Callisto F., Godi R., Marchini G. Polyunsaturated phosphatidylcholine combined with

vitamin B complex in the treatment of patients with disorders of the hepatobiliary function caused by unbalanced nutrition. Clin. Ter., 1989, vol. 131 (4), pp. 237–246.

Sun C., Zheng X., Tan Z., Cui F., Zhang R., Zhang H. Clinical observation on polyene phosphatidylcholine and metformin in the treatment of type-2 diabetes and non-alcoholic fatty liver disease. Clin. Focus, 2008, vol. 23, no. 17.

Yin D., Kong L. Observation for curative effect of Essentiale® in treatment of fatty liver caused by diabetes mellitus. Med. J. Qilu, 2000, vol. 15, pp. 277–278.

Pacifico L., Chiesa C., Anania C., De Merulis A., Osborn J. F., Romaggioli S., Gaudio E. Nonalcoholic fatty liver diseaseand the heart in children and adolescents. World J. Gastroenterol., 2014, vol. 20, pp. 9055–9071.

Forse R. A., Krishnamurty D. M. Epidemiology and Discrimination in Obesity. The ASMBS Textbook of Bariatric Surgery. New York, Springer Publ., 2015, vol. 1, pp. 3–12.

Rzaeva R. N., Mozgovaia E. V., Pal’gova L. K. Steatoz pecheni u zhenshchin s ozhireniem. Osobennosti techeniia beremennosti [Hepatic steatosis in obese women. Peculiarities of pregnancy]. Zhurnal akusherstva i zhenskikh boleznei [Journal of Obstetrics and Women’s Diseases], 2014, vol. LXIII, issue 6, pp. 55–65. (In Russian)

Rzaeva Z. N. Mozgovaia E. V., Pal’gova L. K., Prokopenko V. M., Tumasova Zh. N. Osobennosti

techeniia beremennosti u zhenshchin pri stetoze pecheni i ozhirenii [Peculiarities of pregnancy in women

with liver steatosis and obesity]. Zhurnal akusherstva i zhenskikh boleznei [Journal of Obstetrics and

Women’s Diseases], 2013, vol. LXII, issue 6, pp. 47–54. (In Russian)

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Available at: http://www.journal-of-hepatology.eu/article/S0168-8278(15)00734-5/pdf (accessed 23.09.2016).